Navigation Links
'Possible Key to Alzheimer Medication'
Date:10/26/2010

'Possible Key to Alzheimer Medication' -- LEIDEN, Netherlands, October 26, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

'Possible Key to Alzheimer Medication'

 

LEIDEN, Netherlands, October 26, 2010 /PRNewswire/ -- Dutch researchers have discovered a possible key which might result in a medicine for Alzheimer's disease. "We have found brain cells which become extra active at a time when there are still no visible symptoms of the disease. Nevertheless, people are already ill", says brain researcher Dick Swaab. "It would be fantastic if we could simulate this activation process through medicines once the disease has progressed." The findings of the Dutch scientists, under the auspices of research institute TI Pharma, are due to be published in the reputable scientific magazine Brain.

Scientists examined the brain tissue of 49 deceased patients, in various stages of the disease. In the very earliest stage of the disease, patients did not appear to have any memory impairments or other symptoms of Alzheimer's disease. Under the microscope, however, signs of Alzheimer's are visible. Swaab: "The brain itself appears to compensate for the disease process; nearly 500 genes in the front part of the parahippocampal cortex then become extra active. These genes ensure that nerve cells are better able to communicate with each other, allowing people to continue to function well. As soon as these genes become less active, the memory impairments become apparent."

According to Swaab, this discovery is an important step on the road to finding effective medication. "We see these temporarily active genes as a pointer to a medicine. Once the disease has progressed to a more advanced stage, we can see whether we can reactivate the brain cells using medicines." Swaab adds that a medicine for Alzheimer's will only be a possibility for future generations.

Alzheimer's is the most common cause of dementia. Between sixty and seventy percent of patients suffer from this form of dementia. In Alzheimer's disease, the nerve cells in the brain and the connections between these cells break down, preventing the brain from functioning well. There are an estimated quarter of a million patients in the Netherlands; this number will double in the next forty years.

The research to which among others neuroscientists Dick Swaab, Joost Verhaagen and Koen Bossers from the Netherlands Institute for Neurosciences contribute is funded by Top Instituut Pharma. Other partners are the Netherlands Brain Bank, DNage and health care organization Abbott.

About Top Institute Pharma

Top Institute Pharma (TI Pharma) is a public-private partnership in which the academic and business world work together on innovative, multidisciplinary research targeted toward the improvement of the development of socially valuable medicines. The project portfolio is based on the clinical areas as described in the "Priority Medicines" report from the World Health Organization (WHO). These projects create knowledge that is important for the better, faster and less expensive development of valuable new medicines. For more information, please visit http://www.tipharma.com.


'/>"/>
SOURCE Top Institute Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
2. Denser, more powerful computer chips possible with plasmonic lenses that fly
3. Self-powered devices possible, says Texas A&M researcher
4. Bio-Matrix Scientific Group CEO Tells Wall Street Transcript That Positive Cash Flow Is Possible in 09; New Stem Cell Banking Facility Is Growth Vehicle Over the Next Two Years, Says CEO in Exclusive News Interview
5. New security and medical sensor devices made possible by metallic nanostructures
6. MMR Offers Free Surgical Masks to Call Attention to Importance of Personal Health Records in Preparing for Possible Swine Flu Pandemic
7. Practice makes perfect -- motor memory possible for neuroprosthetic control
8. NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20%
9. Brazilian Sugarcane Industry Association Stresses Need for Brazils Government to Announce Ethanol Import Tariff Cut as Soon as Possible
10. BioSpec Global Solutions Inc. Enters into talks with possible Chinese partner
11. Researchers stretch a lackluster material into a possible electronics revolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... with the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s ... hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
Breaking Biology News(10 mins):